Market Place
Sourcing Support
All News #Library
Biotech
Savara EMA Validates MAA MOLBREEVI Autoimmune PAP
30 Mar 2026 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
13 Feb 2026 //
BUSINESSWIRE
Savara And PARI Secure European Patent For MOLBREEVI* Drug-Device
02 Dec 2025 //
BUSINESSWIRE
Savara To Participate In Investor Healthcare Conferences
20 Nov 2025 //
BUSINESSWIRE
Savara Unveils Q3 2025 Financials & Business Update
12 Nov 2025 //
BUSINESSWIRE
Savara Announces Proposed Public Offering
29 Oct 2025 //
BUSINESSWIRE
Savara secures up to $200M debt financing with Hercules Capital
26 Mar 2025 //
BUSINESSWIRE
Savara Announces Encore Presentation Of Ph 3 IMPALA-2 Trial Results
22 Nov 2024 //
BUSINESSWIRE
Savara Announces New Employment Inducement Grant
22 Nov 2024 //
BUSINESSWIRE
Savara Announces Molgramostim Nebulizer Achieved Significance In IMPALA-2 Trial
26 Jun 2024 //
BUSINESSWIRE
Savara to Host Investor Call on IMPALA-2 Trial Results for Molgramostim in aPAP
25 Jun 2024 //
BUSINESSWIRE
Savara Added to the NASDAQ Biotechnology Index
20 Dec 2023 //
BUSINESSWIRE
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim
26 Jun 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.